Smart-CAR-T: Immuntherapien für feindliche Tumorumgebung wappnen
Welcome to the Hudecek Lab – The home of CAR T
Our research
We are developing novel personalized immune-based cancer treatments that involve reprogramming of the patient’s own immune system cells which are then used to target and destroy cancer cells.
Our approach
We are equipping T cells (white blood cells) with a biosensor (chimeric antigen receptor, CAR) to help them detect and eliminate cancer cells.
Latest publications
Luu, M, Visekruna, A (2022). Targeting metabolic rewiring might decrease spread of tumor cells: Mitochondrial tRNA modifications promote cancer metastasis. Sig Transduct Target Ther 7, 360.
Go to publication
Lock D, Monjezi R, Brandes C, et al (2022). Automated, scaled, transposon-based production of CAR T cells. Journal for ImmunoTherapy of Cancer;10.
Go to publication
Guedan S, Luu M, Ammar D, Barbao P, Bonini C, Bousso P, Buchholz CJ, Casucci M, De Angelis B, Donnadieu E, Espie D, Greco B, Groen R, Huppa JB, Kantari-Mimoun C, Laugel B, Mantock M, Markman JL, Morris E, Quintarelli C, Rade M, Reiche K, Rodriguez-Garcia A, Rodriguez-Madoz JR, Ruggiero E, Themeli M, Hudecek M, Marchiq I (2022). Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside? J Immunother Cancer. May;10(5).
Go to publication
Donnadieu E, Luu M, Alb M, Anliker B, Arcangeli S, Bonini C, De Angelis B, Choudhary R, Espie D, Galy A, Holland C, Ivics Z, Kantari-Mimoun C, Kersten MJ, Köhl U, Kuhn C, Laugel B, Locatelli F, Marchiq I, Markman J, Moresco MA, Morris E, Negre H, Quintarelli C, Rade M, Reiche K, Renner M, Ruggiero E, Sanges C, Stauss H, Themeli M, Van den Brulle J, Hudecek M, Casucci M (2022). Time to evolve: predicting engineered T cell-associated toxicity with next-generation models. J Immunother Cancer. May;10(5).
Go to publication
Brosinsky P, Leister H, Cheng N, Varelas X, Visekruna A, Luu M (2022). Verteporfin protects against Th17 cell-mediated EAE independent of YAP inhibition. Eur J Immunol.
Go to publication
Maucher M, Srour M, Danhof S, Einsele H, Hudecek M, Yakoub-Agha I (2021)
Current Limitations and Perspectives of Chimeric Antigen Receptor-T-Cells in Acute Myeloid Leukemia.
Cancers; 13(24):6157.
Go to publication
See more
Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, Chabannon C, Ciceri F, Corbacioglu S, Ellard R, Sanchez-Guijo F, Jäger U, Hildebrandt M, Hudecek M et al. (2021)
Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA).
Ann Oncol; S0923-7534(21)04876-6.
Go to publication
Luu, M, Visekruna, A (2021)
Microbial metabolites: novel therapeutic tools for boosting cancer therapies.
Trends in Cell Biology, Volume 31, Issue 11.
Go to publication
Jetani, H, Navarro-Bailón, A, Maucheret, M et al. (2021)
Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia (AML).
Blood 2021.
Go to publication
Luu, M, Riester, Z, Baldrich, A et al. (2021)
Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer.
Nat Commun 12, 4077.
Go to publication
Prommersberger, S, Reiser, M, Beckmann, J et al. (2021)
CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma.
Gene Ther 28, 560–571.
Go to publication
Da Vià, M.C., Dietrich, O., Truger, M. et al. (2021)
Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma.
Nat Med 27, 616–619.
Go to publication
Prommersberger S, Hudecek M, Nerreter T. (2020)
Antibody-Based CAR T Cells Produced by Lentiviral Transduction.
Curr Protoc Immunol. Mar;128(1):e93.
Go to publication
VeranstaltungskalenderÜbersicht
No events today.
Contact person
Univ.-Prof. Dr. med.
Michael Hudecek
Director and Research Group Leader Translational CAR-T Research Program